Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 3

Completed

Conditions: Recurrent Melanoma
Stage IIIC Skin Melanoma
Mucosal Melanoma
Stage IIIA Skin Melanoma
Stage IIIB Skin Melanoma
Stage IV Skin Melanoma

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Sorafenib Tosylate
Other: Placebo

First Posted Date: 2005-05-04

Last Posted Date: 2015-10-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 823

Registration Number: NCT00110019

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Bay Area Tumor Institute, Oakland, California, United States
🇺🇸
Kaiser Permanente-Redwood City, Redwood City, California, United States

and more 216 locations

Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma

Phase 2

Active, not recruiting

Conditions: Retinoblastoma

Interventions: Biological: filgrastim
Drug: Carboplatin
Drug: Cyclosporine
Drug: Etoposide
Drug: vincristine sulfate
Procedure: cryosurgery
Procedure: laser therapy

First Posted Date: 2005-05-04

Last Posted Date: 2024-04-17

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 71

Registration Number: NCT00110110

Locations: 🇨🇱
Hospital San Juan de Dios, Santiago, Chile
🇨🇦
Children's and Women's Hospital of British Columbia, Vancouver, British Columbia, Canada
🇮🇳
Sankara Nethralaya Super Specialty Clinic, Chennai, India

and more 3 locations

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: bortezomib
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2005-04-06

Last Posted Date: 2016-12-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 37

Registration Number: NCT00107341

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Phase 1

Completed

Conditions: Lung Cancer
Colorectal Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: carboplatin
Drug: cediranib maleate
Drug: paclitaxel

First Posted Date: 2005-04-06

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 50

Registration Number: NCT00107250

Locations: 🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: pegfilgrastim
Drug: carboplatin
Drug: docetaxel
Procedure: conventional surgery

First Posted Date: 2005-04-06

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 58

Registration Number: NCT00107510

Locations: 🇺🇸
Graham Hospital, Canton, Illinois, United States
🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸
McDonough District Hospital, Macomb, Illinois, United States

and more 114 locations

Irinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2005-03-04

Last Posted Date: 2013-05-30

Lead Sponsor: Japan Multinational Trial Organization

Target Recruit Count: 55

Registration Number: NCT00104793

Locations: 🇯🇵
National Hospital Organization - Medical Center of Kure, Hiroshima, Japan
🇯🇵
Tokyo Medical and Dental University, Tokyo, Japan
🇯🇵
Fujisawa City Hospital, Fujisawa, Kanagawa, Japan

and more 8 locations

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Phase 2

Completed

Conditions: Mesothelioma

Interventions: Drug: pemetrexed disodium
Drug: gemcitabine hydrochloride
Drug: carboplatin

First Posted Date: 2005-01-10

Last Posted Date: 2023-07-03

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 32

Registration Number: NCT00101283

Locations: 🇺🇸
St. Rita's Medical Center, Lima, Ohio, United States
🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States

and more 112 locations

Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-12-09

Last Posted Date: 2013-08-07

Lead Sponsor: NHS Greater Glasgow and Clyde

Target Recruit Count: 1300

Registration Number: NCT00098878

Locations: 🇦🇺
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
🇦🇺
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
🇦🇺
Townsville Hospital, Douglas, Queensland, Australia

and more 85 locations